Every material Form 8-K Healthpeak Properties filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Healthpeak Properties amended and extended its $3 billion senior unsecured revolving credit facility, with the new maturity set at January 19, 2029, and made conforming changes to two term loans. The filing describes routine refinancing terms, with pricing and covenants substantially consistent with the prior agreement, and does not report any change in profit or guidance.
Revolving facility matures January 19, 2029, with two optional six-month extensions
Borrowing capacity can be increased to up to $3.75 billion, subject to conditions
Interest at SOFR plus 0.775% and facility fee of 0.15% based on current debt ratings
Covenants include Consolidated Tangible Net Worth of at least $7.7 billion, tested quarterly
Healthpeak Properties reported third-quarter 2024 results in which AFFO rose to $0.41 per share from $0.40 a year earlier, while Nareit FFO fell to $0.44 from $0.46 and net income was flat at $0.12 per share. The company raised several full-year 2024 guidance ranges, including diluted earnings per share to $0.40 to $0.42 from $0.27 to $0.31, and declared a $0.30 quarterly dividend.
Q3 2024 AFFO of $0.41 per share versus $0.40 in Q3 2023; Nareit FFO of $0.44 versus $0.46; net income of $0.12 per share, unchanged.
2024 diluted EPS guidance raised to $0.40 to $0.42 from $0.27 to $0.31; AFFO guidance raised to $1.56 to $1.58 from $1.54 to $1.58.
Quarterly common dividend of $0.30 per share declared October 23, 2024, payable November 15, 2024 to holders of record on November 4, 2024.
Expected 2024 merger-related synergies raised to approximately $50 million from the Physicians Realty Trust merger.
Healthpeak Properties reported second-quarter 2024 results on July 25, 2024, with diluted net income of $0.21 per share, up from $0.09 a year earlier, while Nareit FFO was $0.44 per share, down from $0.45. The company raised its full-year 2024 diluted earnings per share guidance to $0.27 to $0.31 from $0.16 to $0.20. For shareholders, higher earnings guidance is offset in part by a slight decline in FFO per share, a key REIT measure.
Q2 2024 diluted net income of $0.21 per share vs. $0.09 in Q2 2023; Nareit FFO $0.44 vs. $0.45; AFFO $0.39 vs. $0.40
Full-year 2024 diluted EPS guidance raised to $0.27 to $0.31 from $0.16 to $0.20; diluted Nareit FFO guidance raised to $1.59 to $1.63 from $1.56 to $1.60
Quarterly common dividend of $0.30 per share declared July 24, 2024, payable August 16, 2024, to holders of record on August 5, 2024
New $500 million share repurchase authorization effective through July 2026, replacing the existing authorization
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Healthpeak Properties filing is on SEC EDGAR ↗. 8-K briefs of other companies →